< News, Press, & Events

Press Release

Genomenon and Deep 6 AI Sign Proof of Concept Agreement to Increase Clinical Trial Matching Capabilities

November 4, 2021 Ann Arbor, Michigan

Genomenon and Deep 6 AI Sign Proof of Concept Agreement to Increase Clinical Trial Matching Capabilities

Precision matching leveraging genomic landscapes to enable earlier identification and pre-diagnosis of cancer, Parkinson, and Wilson disease

Genomenon, Inc.®, an AI-driven genomics company, today announced a Proof of Concept Agreement with Deep 6 AI, the leader in artificial intelligence (AI)-based clinical trial acceleration software (CTAS). The collaboration offers significant value to disease researchers, clinical operations, and precision matched recruitment, accelerating the identification and treatment of diseases such as cancer, Parkinson, and Wilson disease. On Tuesday October 9 at 11AM EST at the CNS Summit 2021, Deep 6 AI’s VP of life sciences Jason Attanucci will co-present results of a CNS study utilizing the company’s precision matching capabilities.

“Genomenon’s AI-driven Genomic Landscapes deliver a profound understanding of the drivers and clinical attributes of any genetic disease, from neurodegenerative and rare diseases to cancer,” said Mike Klein, CEO of Genomenon. “Our collaboration with Deep 6 AI will help patients who will benefit from matching knowledge, while our Genomic Landscapes enable pharma to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval.”

"Precision matching is at the heart of our mission to support precision medicine and rapidly deliver more targeted therapies to patients,” said Jason Attanucci, vice president of life sciences at Deep 6 AI. “Together, both Genomenon and Deep 6 AI will provide a combined, AI-driven understanding of disease, enabling actionable insight into their genetic drivers, clinical representation, and comorbidity."


Genomenon is a genomics intelligence company dedicated to improving the quality of life of genetic disease and cancer patients by making genomic information actionable. Blending the power of AI with the precision of genomic expertise, the company empowers pharmaceutical companies and the clinical diagnostic community with empirical genomic evidence and insights that both support the development of novel therapeutics and speed diagnostic assessments and treatment recommendations.

Deep 6 AI

Deep 6 AI develops clinical trial acceleration software to bring the right therapies to patients faster. The company’s flagship platform uses artificial intelligence (AI) concepts such as natural language processing (NLP) and machine learning (ML) to analyze both structured and unstructured data, precision matching research criteria to patient characteristics in minutes instead of months. The platform connects sponsors, clinical researchers, physicians, and patients in a rapidly growing real-world ecosystem of premier research organizations.

Built by expert researchers, scientists, and technologists from a myriad of disciplines, Deep 6 AI’s technology results in fewer false positives, greater access to investigational treatments for patients, more successful trials, and faster time to market. Deep 6 AI is a Techstars and StartX alum. The company was founded in 2016 and is based in Pasadena, CA. Learn more at https://deep6.ai.

Read the Article
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.